NERVGEN PHARMA CORP (NGEN) Fundamental Analysis & Valuation

NASDAQ:NGEN • CA64082X2032

Current stock price

3.62 USD
-0.13 (-3.47%)
Last:

This NGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NGEN Profitability Analysis

1.1 Basic Checks

  • NGEN had negative earnings in the past year.
  • In the past year NGEN has reported a negative cash flow from operations.
  • NGEN had negative earnings in each of the past 5 years.
  • NGEN had a negative operating cash flow in each of the past 5 years.
NGEN Yearly Net Income VS EBIT VS OCF VS FCFNGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -197.42%, NGEN is doing worse than 91.10% of the companies in the same industry.
Industry RankSector Rank
ROA -197.42%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NGEN Yearly ROA, ROE, ROICNGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGEN Yearly Profit, Operating, Gross MarginsNGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. NGEN Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for NGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NGEN Yearly Shares OutstandingNGEN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
NGEN Yearly Total Debt VS Total AssetsNGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -1.27, we must say that NGEN is in the distress zone and has some risk of bankruptcy.
  • NGEN has a Altman-Z score (-1.27) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.27
ROIC/WACCN/A
WACCN/A
NGEN Yearly LT Debt VS Equity VS FCFNGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • A Current Ratio of 0.79 indicates that NGEN may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.79, NGEN is doing worse than 91.10% of the companies in the same industry.
  • NGEN has a Quick Ratio of 0.79. This is a bad value and indicates that NGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NGEN's Quick ratio of 0.79 is on the low side compared to the rest of the industry. NGEN is outperformed by 86.39% of its industry peers.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.79
NGEN Yearly Current Assets VS Current LiabilitesNGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NGEN Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 2.11% over the past year.
EPS 1Y (TTM)2.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 50.55% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.97%
EPS Next 2Y7.18%
EPS Next 3Y8.54%
EPS Next 5Y50.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NGEN Yearly Revenue VS EstimatesNGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
NGEN Yearly EPS VS EstimatesNGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. NGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NGEN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGEN Price Earnings VS Forward Price EarningsNGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGEN Per share dataNGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.05 -0.1 -0.15 -0.2 -0.25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.18%
EPS Next 3Y8.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NGEN Dividend Analysis

5.1 Amount

  • NGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NGEN Fundamentals: All Metrics, Ratios and Statistics

NERVGEN PHARMA CORP

NASDAQ:NGEN (4/30/2026, 3:41:09 PM)

3.62

-0.13 (-3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength39.37
Industry Growth47.76
Earnings (Last)03-31
Earnings (Next)05-14
Inst Owners0.06%
Inst Owner ChangeN/A
Ins Owners2.72%
Ins Owner ChangeN/A
Market Cap291.55M
Revenue(TTM)N/A
Net Income(TTM)-25.82M
Analysts80
Price Target5.7 (57.46%)
Short Float %2%
Short Ratio7.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-78.22%
Min EPS beat(2)-157.43%
Max EPS beat(2)0.99%
EPS beat(4)2
Avg EPS beat(4)-43.47%
Min EPS beat(4)-157.43%
Max EPS beat(4)33.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-58.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -197.42%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.79
Altman-Z -1.27
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)38.62%
Cap/Depr(5y)46.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y24.97%
EPS Next 2Y7.18%
EPS Next 3Y8.54%
EPS Next 5Y50.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.38%
OCF growth 3YN/A
OCF growth 5YN/A

NERVGEN PHARMA CORP / NGEN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NERVGEN PHARMA CORP (NGEN) stock?

ChartMill assigns a fundamental rating of 1 / 10 to NGEN.


What is the valuation status of NERVGEN PHARMA CORP (NGEN) stock?

ChartMill assigns a valuation rating of 0 / 10 to NERVGEN PHARMA CORP (NGEN). This can be considered as Overvalued.


How profitable is NERVGEN PHARMA CORP (NGEN) stock?

NERVGEN PHARMA CORP (NGEN) has a profitability rating of 0 / 10.


Can you provide the financial health for NGEN stock?

The financial health rating of NERVGEN PHARMA CORP (NGEN) is 1 / 10.